Skip to content

Fluid Restriction and Quality of Life on Dialysis

Exploring the Effects of a Brief Values-Based Intervention on Adherence to Fluid Restriction Recommendations and Quality of Life in Haemodialysis Patients

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05264220
Enrollment
8
Registered
2022-03-03
Start date
2022-03-15
Completion date
2022-10-15
Last updated
2022-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

End Stage Renal Disease

Brief summary

Almost 30,000 people in the UK receive dialysis due to end stage renal disease (ESRD). Although dialysis prolongs life, people receiving dialysis are still typically bothered by a range of physical symptoms and need to make substantial adjustments in order to accommodate ESRD and its treatment. One adjustment that is often required is a dramatic reduction in fluid intake. Although sticking to fluid intake restrictions improves the efficiency of dialysis, monitoring fluid intake is complicated. The restrictions also leave people feeling very thirsty so restrictions can be hard to stick to. This project will develop and test a brief psychological intervention for people who struggle to adhere to fluid intake restrictions and will aim to increase quality of life whilst on dialysis. The intervention will be developed with input from people with lived experience of ESRD. It will then be offered to 12 people, recruited from clinics, who will complete questionnaires to monitor experiences and symptoms before, during and after the intervention. Participants' data will be analysed to find out whether the intervention has been helpful in reducing fluid intake and improving quality of life. If the findings are promising, this would suggest that the intervention could be tested in a larger clinical study in the future.

Detailed description

Please note: this study adopts a between-subjects concurrent multiple baseline single case ABC experimental design. Participant change within and across phases A (baseline, variable with participants randomised to a 6, 8, or 10 week baseline), B (4 week intervention phase) and C (4 week follow-up) will be explored.

Interventions

BEHAVIORALACT Matrix

Participants will receive a 4 session psychological intervention based on the ACT Matrix

Sponsors

Oxford University Hospitals NHS Trust
CollaboratorOTHER
Oxford Health NHS Foundation Trust
CollaboratorOTHER_GOV
University of Oxford
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Single group study - multiple baseline case series

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Currently receiving haemodialysis for end-stage kidney disease * Aged 18+ * Adequate fluency in written and spoken English to undertake the intervention and complete measures (assessed by research psychologist during discussion of study commitment) * Willing and able to participate in face-to-face and/or digital delivery of a psychological intervention (e.g. if digital delivery is requested or/or necessitated by Covid 19 restrictions patient has access to a computer, tablet or phone). * Identified by clinical staff as having difficulty with adherence to fluid intake recommendations. * Consents to participation, including recording of video sessions for fidelity/adherence rating and supervision.

Exclusion criteria

* • Lack of capacity to consent * Poorly controlled diabetes resulting in recent hospital admissions for hypo/hyperglycaemic episode(s) * Intellectual disability that prevents self-management of fluid intake

Design outcomes

Primary

MeasureTime frameDescription
Dialysis Diet and Fluid Intake Non-Adherence Questionnaire (Vlamink et al., 2001)baseline phase week 2This brief four-item measure assesses adherence to diet and fluid requirements over the previous 14 days. It includes the following items: 1) On how many days during the last 14 didn't you follow your diet guidelines? 2) To what degree did you deviate from your diet guidelines? (0-no deviation to 4 - very severe deviation) 3) On how many days during the last 14 didn't you follow your fluid guidelines? 4) To what degree did you deviate from your fluid guidelines? (0-no deviation to 4 - very severe deviation).
Interdialytic weight gainBaseline phase week 1participant's interdialytic weight gain between each dialysis session will be obtained from medical records if possible.

Secondary

MeasureTime frameDescription
Valuing Questionnairebaseline week 1This 10-item questionnaire assesses wellbeing as it relates to a person's ability to live the kind of life they value. It is designed for weekly administration. Items include statements such as I made progress in the areas of life I care most about and my behaviour was a good example of what I stand for in life. Each item is rated on a scale ranging from 1 (not at all true) to 7 (completely true).

Other

MeasureTime frameDescription
Dialysis Symptoms Index (Weisbord et al., 2004)Baseline week 1Measure of common physical and psychological symptoms experienced by people on dialysis
End-Stage Renal Disease Adherence Questionnaire (ESRD-AQ; Kim et al., 2010)Study intake assessmentThis self-report measure includes 46 questions assessing adherence to medication, diet, fluid intake restrictions and participation in dialysis sessions. It has excellent psychometric properties.
Intervention Credibility/Expectancy Questionnaire (Devilly & Borkovec, 2000)Intervention week 1measure of participants' views on intervention credibility
CompACT (Francis, Dawson & Golijani-Moghaddam, 2016)Baseline week 1This 23-item questionnaire assesses psychological flexibility. In addition to a total score, three subscale scores reflecting openness to experience, behavioural awareness and valued action can be derived. Each item is rated on a scale ranging from 0 (strongly disagree) to 6 (strongly agree).
The Clinical Outcomes Routine Evaluation (CORE) -10 (Barkham et al., 2013)Baseline week 1This measure assesses severity of clinical symptoms, across 10 items, each rated 0-4. The measure differentiates clinical samples from non-clinical populations. It has adequate convergent validity when correlated with other clinical measures, and good internal reliability (Cronbach's alpha \> .80) and sensitivity to change (see Connell & Barkham, 2007). A change on the CORE-10 of six or more points corresponds to statistically reliable change. Scores on the measure are interpreted as follows: 0-5 (healthy); 6-10 (low level); 11-15 (mild); 16-20 (moderate); 21-25 (moderately severe); 26 + (severe).
EQ-5D-5L (EuroQuol Group, 2009).Baseline phase week 1This widely used measure assesses quality of life across five domains: mobility, self-care, usual activities, pain / discomfort, anxiety/depression. Each domain is rated on a five-level scale: no problems, slight problems, moderate problems, severe problems, unable to/extreme problems. Additionally, respondents complete a health thermometer rating their current health status on a scale from 0 to 100. The EQ-5D-5L is a widely used measure for assessing health status with normative data available for UK samples.

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026